Company profile
Climb Bio, Inc.
NASDAQ: CLYM · Healthcare · Biotechnology
PublicHQ Wellesley Hills, DECIK 0001768446Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 62DQ —GM —SS 46
v0.1 · 35/100 weight · pillars only
↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$59.9M
Employees
28
as of 2026-09-11
Market cap
$856.1M
as of 2026-09-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$59.9M-$59.9M2025
Operating income-$67.9M-$67.9M2025
Total assets$167.7M$167.7M2025
Liabilities$7.3M$7.3M2025
Equity$160.5M$160.5M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Climb Bio, Inc.’s financial profile?
Climb Bio, Inc. earned -$59.9M in FY2025 net income.
Peers · Healthcare
Olema Pharmaceuticals, Inc.——Sana Biotechnology, Inc.——SpyGlass Pharma, Inc. Common Stock——Cybin Inc. Common Stock——Adlai Nortye Ltd.——Aura Biosciences, Inc.——Key facts
CEOAoife Brennan BCh MMSc
SectorHealthcare
IndustryBiotechnology
HeadquartersWellesley Hills, DE
ExchangeNASDAQ: CLYM
Employees28
IPO date2021-08-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.